Holding unique IP, MGC Pharmaceuticals’ Innovation division puts the Company at the forefront of exploration and development into indications that will serve large global markets.
Having recently attained interim GMP Certification at our European facility, MGC Pharma has commenced the full-scale commercial production of CannEpilTM and will soon start clinical studies in epilepsy, based in Slovenia, in addition to ongoing advancement of supplement and nutraceutical products. MGC also hopes to offer patients in Australia with these products and generate revenue from API sales.
Innovation Division: Having recently attained interim GMP Certification at our European facility, we can soon commence clinical studies in epilepsy, based in Slovenia.
Alongside these trials, we will also continue to work on the development of nutraceuticals and supplement products.
We also hope to make progress on providing patients in the Australian market with these products, as well as generate revenue from API sales.
Lenis: MGC Pharmaceuticals Ltd has signed a 5-year, Supply and Distribution Agreement with European pharmaceutical distribution company, Lenis farmacevtika d.o.o. (Lenis).
Epilepsy Action Australia: MGC Pharmaceuticals Ltd has signed a collaboration agreement with Australia’s leading Epilepsy association on future joint clinical trials.
HL Pharma: MGC Pharmaceuticals Ltd Australian Supply and Distribution company.